Related Experiment Video
Updated: Jan 3, 2026
Performing Data Mining And Integrative Analysis Of Biomarker in Breast Cancer Using Multiple Publicly Accessible Databases
Published on: May 17, 2019
Down Regulation of KAI1/CD82 in Lymph Node Positive and Advanced T-Stage Group in Breast Cancer Patients
Thammineni Krishna Latha1, Ankur Verma2, Gaurav Kumar Thakur1
1Department of Biochemistry University College of Medical Sciences and GTB Hospital , University of Delhi, Dilshad Garden, Delhi, India.
Background:
Metastasis represents a deadly aspect of any cancer including breast cancer, given its high prevalence; treatment of metastatic breast cancer remains a clinically unmet need, which necessitates the exploration of metastasis suppressor genes (MSGs). KAI-1/CD82 is an important member of MSGs; the role of KAI1 has been well explored in prostate cancer, however its role in breast cancer is not fully explored and in fact the results of breast cancer studies are contentious. Thus, the present study aimed to investigate expression of KAI1 at both transcriptional and translational levels in the tissue of breast cancer patients and benign breast disease. Further, we analysed the relationship between expression levels of KAI1 and clinicopathological parameters in breast cancer patients.
Materials And Methods:
mRNA expression was studied by Real time PCR and protein expression was analyzed by both Western blot and Immunohistochemistry.
Results:
The results of the study indicate that KAI1 expression was remarkably decreased in breast cancer both at the gene and the protein levels (P < 0.05) compared to benign breast disease. In addition, KAI1 expression levels were strongly associated with axillary lymph node status and advanced T stage (p < 0.05), however no association was found with tumor grade, age, menopausal status and receptor status like ER, PR and Her2.
Conclusion:
Low expression of KAI1 might be helpful for predicting the lymph node metastasis and T staging, thus predicts malignant prognosis of breast cancer.
.
Insights
Reduced expression of KAI-1 (also known as CD82) in breast cancer tissues correlates with advanced tumor stage and lymph node metastasis. This finding suggests KAI-1 may serve as a prognostic biomarker for breast cancer.
Area of Science:
- Oncology
- Molecular Biology
- Cancer Research
Background:
- Metastasis is a critical factor in breast cancer mortality, highlighting the need for metastasis suppressor genes (MSGs).
- KAI-1/CD82 is a known MSG, but its role in breast cancer is not fully understood, with conflicting study results.
- Investigating KAI-1 expression and its correlation with clinical parameters is crucial for understanding breast cancer progression.
Purpose of the Study:
- To investigate KAI-1 expression at both the gene and protein levels in breast cancer tissues and benign breast disease.
- To analyze the relationship between KAI-1 expression and clinicopathological parameters in breast cancer patients.
Main Methods:
- Gene expression was quantified using Real-time PCR.
- Protein expression was assessed via Western blot and Immunohistochemistry.
Main Results:
- KAI-1 expression was significantly decreased in breast cancer tissues compared to benign tissues at both mRNA and protein levels.
- Lower KAI-1 expression was strongly associated with axillary lymph node metastasis and advanced T stage.
- No significant association was found between KAI-1 expression and tumor grade, age, menopausal status, or receptor status (ER, PR, Her2).
Conclusions:
- Decreased KAI-1 expression may serve as a predictive marker for lymph node metastasis and T staging in breast cancer.
- Low KAI-1 expression could indicate a poorer prognosis for breast cancer patients.
More Related Videos
Related Concept Videos
01:15Receptor Downregulation in MVBs
The EGFR can initiate signaling pathways that lead to cell proliferation, migration, and differentiation. Overexpression of EGFR stimulates cells to proliferate. Excessive EGFR...
02:34Inhibition of Cdk Activity